​

BridgeBio Oncology Therapeutics Ownership | Who Owns BridgeBio Oncology Therapeutics?

OverviewFinancialsChart

BridgeBio Oncology Therapeutics Ownership Summary

BridgeBio Oncology Therapeutics is owned by 241.66% institutional investors, 24.05% insiders.

BBOT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockBridgeBio Oncology Therapeutics241.66%24.05%-165.71%
SectorHealthcare Stocks 42.54%10.82%46.64%
IndustryBiotech Stocks 45.21%10.75%44.04%

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202540-56,812,263-241-40---

Insider Transactions Trends

DateBuySell
2025 Q4--
2025 Q3--

BBOT Ownership FAQ

Who Owns BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics shareholders are primarily institutional investors at 241.66%, followed by 24.05% insiders and -165.71% retail investors. The average institutional ownership in BridgeBio Oncology Therapeutics's industry, Biotech Stocks , is 45.21%, which BridgeBio Oncology Therapeutics exceeds.

Does Blackrock own BridgeBio Oncology Therapeutics?

BlackRock is not among the top 10 institutional shareholders of BridgeBio Oncology Therapeutics.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools